These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Synthesis and Lavanya KJ; Kaur K; Jaitak V Curr Comput Aided Drug Des; 2024; 20(4):374-383. PubMed ID: 36944620 [TBL] [Abstract][Full Text] [Related]
23. Multitargeted Molecular Docking Study of Natural-Derived Alkaloids on Breast Cancer Pathway Components. Singla R; Jaitak V Curr Comput Aided Drug Des; 2017 Nov; 13(4):294-302. PubMed ID: 28382865 [TBL] [Abstract][Full Text] [Related]
24. Identification of pseudobaptigenin as a novel polyphenol-based multi-target antagonist of different hormone receptors for breast cancer therapeutics. Ray S; Gupta S; Panda G; Chatterjee P; Das A; Patawri P; Hosseinzadeh P; Ray A; Banerjee S J Biomol Struct Dyn; 2024 Jul; 42(11):5502-5514. PubMed ID: 37409735 [TBL] [Abstract][Full Text] [Related]
25. Computational Screening of Some Phytochemicals to Identify Best Modulators for Ligand Binding Domain of Estrogen Receptor Alpha. Alagarsamy V; Sundar PS; Solomon VR; Murugesan S; Muzaffar-Ur-Rehman M; Kulkarni VS; Sulthana MT; Narendhar B; Sabarees G Curr Pharm Des; 2024; 30(20):1599-1609. PubMed ID: 38698754 [TBL] [Abstract][Full Text] [Related]
26. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer. Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422 [TBL] [Abstract][Full Text] [Related]
27. Identification of Estrogen Receptor Pang X; Fu W; Wang J; Kang D; Xu L; Zhao Y; Liu AL; Du GH Oxid Med Cell Longev; 2018; 2018():6040149. PubMed ID: 29861831 [TBL] [Abstract][Full Text] [Related]
28. Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer. Singaram K; Marimuthu D; Baskaran S; Chinaga SK; Shanmugarajan D; Vadivel T Comb Chem High Throughput Screen; 2017; 20(8):703-712. PubMed ID: 28738766 [TBL] [Abstract][Full Text] [Related]
30. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells. Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451 [TBL] [Abstract][Full Text] [Related]
31. Natural Products as Chemopreventive Agents by Potential Inhibition of the Kinase Domain in ErbB Receptors. Olivero-Acosta M; Maldonado-Rojas W; Olivero-Verbel J Molecules; 2017 Feb; 22(2):. PubMed ID: 28218686 [TBL] [Abstract][Full Text] [Related]
32. Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer. Li J; Wang H; Li J; Bao J; Wu C Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27376283 [TBL] [Abstract][Full Text] [Related]
33. In silico assessment of new progesterone receptor inhibitors using molecular dynamics: a new insight into breast cancer treatment. Zarezade V; Abolghasemi M; Rahim F; Veisi A; Behbahani M J Mol Model; 2018 Nov; 24(12):337. PubMed ID: 30415281 [TBL] [Abstract][Full Text] [Related]
34. Identification of novel chemical scaffolds against kinase domain of cancer causing human epidermal growth factor receptor 2: a systemic chemoinformatic approach. Alrumaihi F J Biomol Struct Dyn; 2024 Aug; 42(12):6269-6279. PubMed ID: 37424103 [TBL] [Abstract][Full Text] [Related]
35. In silico molecular docking and dynamic simulation of eugenol compounds against breast cancer. Rasul HO; Aziz BK; Ghafour DD; Kivrak A J Mol Model; 2021 Dec; 28(1):17. PubMed ID: 34962586 [TBL] [Abstract][Full Text] [Related]
36. Computational prediction for designing novel ketonic derivatives as potential inhibitors for breast cancer: A trade-off between drug likeness and inhibition potency. Muhammad S; Zahir N; Bibi S; Alshahrani MY; Shafiq-urRehman ; Chaudhry AR; Sarwar F; Tousif MI Comput Biol Chem; 2024 Apr; 109():108020. PubMed ID: 38286082 [TBL] [Abstract][Full Text] [Related]
37. Integrated approach for studying bioactive compounds from Cladosporium spp. against estrogen receptor alpha as breast cancer drug target. Anandan S; Gowtham HG; Shivakumara CS; Thampy A; Singh SB; Murali M; Shivamallu C; Pradeep S; Shilpa N; Shati AA; Alfaifi MY; Elbehairi SEI; Ortega-Castro J; Frau J; Flores-Holguín N; Kollur SP; Glossman-Mitnik D Sci Rep; 2022 Dec; 12(1):22446. PubMed ID: 36575224 [TBL] [Abstract][Full Text] [Related]
38. Dual functionality of pyrimidine and flavone in targeting genomic variants of EGFR and ER receptors to influence the differential survival rates in breast cancer patients. Avti PK; Singh J; Dahiya D; Khanduja KL Integr Biol (Camb); 2023 Apr; 15():. PubMed ID: 38084900 [TBL] [Abstract][Full Text] [Related]
39. Switching from Aromatase Inhibitors to Dual Targeting Flavonoid-Based Compounds for Breast Cancer Treatment. Gobbi S; Martini S; Rozza R; Spinello A; Caciolla J; Rampa A; Belluti F; Zaffaroni N; Magistrato A; Bisi A Molecules; 2023 Mar; 28(7):. PubMed ID: 37049810 [TBL] [Abstract][Full Text] [Related]